Q-omics provides the consensus-scored CACNA1B profile across patient tissues and cancer cell-line models. CACNA1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CACNA1B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CACNA1B RNA expression shows 22,880 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where CACNA1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1B survival associations across molecular data types. CACNA1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1B RNA expression–survival associations across cancer types. High CACNA1B expression shows unfavorable associations in UCEC, BRCA, KIRC and KIRP, but favorable associations in HNSC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CACNA1B RNA expression.
This table summarizes CACNA1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1B shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in HNSC, LUSC and BRCA. The HNSC box plot shows higher CACNA1B RNA expression in tumor versus normal tissue (log2 FC = +1.116, t-test p < 0.001).
This table shows molecular features associated with CACNA1B in patient tissues and cancer cell lines. In patient samples, CACNA1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
